Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Files An 8-K Regulation FD Disclosure

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Story continues below

On July 17, 2018, Eisai Inc. reported positive top line results from CAMELLIA-TIMI61, a cardiovascular outcome trial for the anti-obesity agent BELVIQ®. BELVIQ was discovered and developed by Arena and is the subject of a Transaction Agreement entered into as of December 28, 2016, to which Arena licensed and transferred rights to Eisai for BELVIQ in exchange for a royalty on net sales and other payments. Additional information regarding the study results is provided in Eisai’s press release of the same date titled “Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®.”

About Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that target G protein-coupled receptors (GPCRs). The Company’s drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management, and is being commercialized under the brand name, BELVIQ. The Company’s drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. APD334 is an orally available modulator of the sphingosine 1-phosphate subtype 1 (S1P1) receptor intended for the treatment of multiple sclerosis, psoriasis, inflammatory bowel diseases and rheumatoid arthritis. The Company’s programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases and an undisclosed orphan GPCR for central nervous system indication(s).

An ad to help with our costs